Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
August 21, 2024 09:00 ET
|
GeoVax, Inc.
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax...
Africa Monkeypox Vaccine and Treatment Market Trends Analysis, Market Size and Forecasts to 2030
August 21, 2024 07:02 ET
|
Research and Markets
Dublin, Aug. 21, 2024 (GLOBE NEWSWIRE) -- The "Africa Monkeypox Vaccine and Treatment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2030" report has been added to ...
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
August 15, 2024 09:00 ET
|
GeoVax, Inc.
Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
Anti-Venom Market Size, Share & Trends Analysis Report 2024-2030
August 14, 2024 07:28 ET
|
Research and Markets
Dublin, Aug. 14, 2024 (GLOBE NEWSWIRE) -- The "Anti-venom Market Size, Share & Trends Analysis Report By Species (Snake, Scorpion), By Type (Polyvalent, Monovalent), By Mode Of Action...
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
August 13, 2024 16:05 ET
|
Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
August 08, 2024 09:00 ET
|
GeoVax, Inc.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024 16:05 ET
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or...
Airfinity US RSV vaccine market estimate cut by 64% from $4.7bn to $1.7bn a year by 2030 following recommendations for single lifetime shot for elderly people
July 24, 2024 02:00 ET
|
Airfinity
London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...
Antivenoms Global Market Insights and Outlook 2024-2030: A $2.3 Billion Opportunity with Snake Antivenoms Accounting for ~87% Share of the Total Market - BTG PLC Leads the Competition, Followed by CSL Ltd.
July 18, 2024 09:08 ET
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Antivenoms - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Antivenoms is...
Evaxion Showcases Improved Performance of Key Building Block in AI-Immunology™ at Computational Biology Conference
July 16, 2024 07:30 ET
|
Evaxion Biotech
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art...